Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Multaq dronedarone: Phase III data

In the double-blind, international Phase III ADONIS trial in 625 patients, the median time to recurrence of

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE